Gilteritinib is a medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is primarily used in the treatment of a specific type of blood cancer called acute myeloid leukemia (AML) with a FLT3 mutation. This mutation is present in approximately one-third of patients with AML and is associated with a poorer prognosis.

Gilteritinib works by targeting and inhibiting the activity of the FLT3 protein, which plays a key role in the growth and survival of cancer cells. By blocking this protein, gilteritinib helps to slow down the progression of the disease and improve outcomes for patients with FLT3-mutated AML.

As with any medication, gilteritinib may cause side effects in some patients. Common side effects may include nausea, vomiting, diarrhea, fatigue, and elevated liver enzymes. It is important to discuss any side effects with your healthcare provider, as they may be able to provide guidance on how to manage them.

It is crucial to take gilteritinib exactly as prescribed by your healthcare provider. Missing doses or stopping the medication prematurely can reduce its effectiveness and may not provide the desired benefits. Your healthcare provider will monitor your progress closely while taking gilteritinib to ensure that it is working effectively and to make any necessary adjustments to your treatment plan.

Overall, gilteritinib is a valuable treatment option for patients with FLT3-mutated AML. It has shown promising results in clinical trials and has the potential to improve outcomes for individuals with this challenging form of leukemia. If you have been prescribed gilteritinib, be sure to follow your healthcare provider’s instructions carefully and communicate any concerns or questions you may have.